<DOC>
	<DOCNO>NCT00014729</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine safety isotretinoin patient recessive dystrophic epidermolysis bullosa .</brief_summary>
	<brief_title>Phase I Study Isotretinoin Patients With Recessive Dystrophic Epidermolysis Bullosa</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive oral isotretinoin daily 8 month absence disease progression unacceptable toxicity . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis recessive dystrophic epidermolysis bullosa ( RDEB ) RDEB HallopeauSiemens OR RDEB nonHallopeauSiemens Concurrent enrollment National Epidermolysis Bullosa Registry No regional distant metastasis patient previous concurrent squamous cell carcinoma Patient Characteristics Hepatic : No clinically significant hypertriglyceridemia No clinically significant hepatic dysfunction Renal : No clinically significant renal dysfunction Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2001</verification_date>
	<keyword>dermatologic disorder</keyword>
	<keyword>epidermolysis bullosa</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>rare disease</keyword>
</DOC>